Last reviewed · How we verify

Photocil for Atopic Dermatitis

Applied Biology, Inc. · Phase 1 active Small molecule

Photocil for Atopic Dermatitis is a Small molecule drug developed by Applied Biology, Inc.. It is currently in Phase 1 development. Also known as: Photocil for Atopic Dermatitis (U.S. FDA NDC: 54841-001-01).

At a glance

Generic namePhotocil for Atopic Dermatitis
Also known asPhotocil for Atopic Dermatitis (U.S. FDA NDC: 54841-001-01)
SponsorApplied Biology, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Photocil for Atopic Dermatitis

What is Photocil for Atopic Dermatitis?

Photocil for Atopic Dermatitis is a Small molecule drug developed by Applied Biology, Inc..

Who makes Photocil for Atopic Dermatitis?

Photocil for Atopic Dermatitis is developed by Applied Biology, Inc. (see full Applied Biology, Inc. pipeline at /company/applied-biology-inc).

Is Photocil for Atopic Dermatitis also known as anything else?

Photocil for Atopic Dermatitis is also known as Photocil for Atopic Dermatitis (U.S. FDA NDC: 54841-001-01).

What development phase is Photocil for Atopic Dermatitis in?

Photocil for Atopic Dermatitis is in Phase 1.

Related